178 related articles for article (PubMed ID: 30795774)
1. Effects of three long-acting reversible contraceptive methods on HIV target cells in the human uterine cervix and peripheral blood.
Li L; Zhou J; Wang W; Huang L; Tu J; Baiamonte L; Stark M; Mills M; Hope TJ; Drobnis EZ; Quayle AJ; Schust DJ
Reprod Biol Endocrinol; 2019 Feb; 17(1):26. PubMed ID: 30795774
[TBL] [Abstract][Full Text] [Related]
2. CCR5 Expression Levels in HIV-Uninfected Women Receiving Hormonal Contraception.
Sciaranghella G; Wang C; Hu H; Anastos K; Merhi Z; Nowicki M; Stanczyk FZ; Greenblatt RM; Cohen M; Golub ET; Watts DH; Alter G; Young MA; Tsibris AM
J Infect Dis; 2015 Nov; 212(9):1397-401. PubMed ID: 25895986
[TBL] [Abstract][Full Text] [Related]
3. Increased Cervical CD4
Lajoie J; Tjernlund A; Omollo K; Edfeldt G; Röhl M; Boily-Larouche G; Cheruiyot J; Kimani M; Kimani J; Oyugi J; Broliden K; Fowke KR
AIDS Res Hum Retroviruses; 2019 Mar; 35(3):236-246. PubMed ID: 30585733
[TBL] [Abstract][Full Text] [Related]
4. Effect of progestins on immunity: medroxyprogesterone but not norethisterone or levonorgestrel suppresses the function of T cells and pDCs.
Huijbregts RP; Michel KG; Hel Z
Contraception; 2014 Aug; 90(2):123-9. PubMed ID: 24674041
[TBL] [Abstract][Full Text] [Related]
5. Effect of the depot medroxyprogesterone acetate injectable and levonorgestrel implant on HIV genital shedding: a randomized trial.
Chinula L; Nelson JAE; Wiener J; Tang JH; Hurst S; Tegha G; Msika A; Ellington S; Hosseinipour MC; Mataya R; Haddad LB; Kourtis AP
Contraception; 2018 Sep; 98(3):193-198. PubMed ID: 29746813
[TBL] [Abstract][Full Text] [Related]
6. Effects of Depot Medroxyprogesterone Acetate, Copper Intrauterine Devices, and Levonorgestrel Implants on Early HIV Disease Progression.
Morrison CS; Hofmeyr GJ; Thomas KK; Rees H; Philip N; Palanee-Phillips T; Nanda K; Nair G; Onono M; Mastro TD; Lind M; Heffron R; Edward V; Deese J; Beksinska M; Beesham I; Stringer JSA; Baeten JM; Ahmed K;
AIDS Res Hum Retroviruses; 2020 Aug; 36(8):632-640. PubMed ID: 32394723
[TBL] [Abstract][Full Text] [Related]
7. Initiating Intramuscular Depot Medroxyprogesterone Acetate Increases Frequencies of Th17-like Human Immunodeficiency Virus Target Cells in the Genital Tract of Women in South Africa: A Randomized Trial.
Bunjun R; Ramla TF; Jaumdally SZ; Noël-Romas L; Ayele H; Brown BP; Gamieldien H; Harryparsad R; Dabee S; Nair G; Onono M; Palanee-Phillips T; Scoville CW; Heller KB; Baeten JM; Bosinger SE; Burgener A; Passmore JS; Jaspan H; Heffron R
Clin Infect Dis; 2022 Nov; 75(11):2000-2011. PubMed ID: 35941737
[TBL] [Abstract][Full Text] [Related]
8. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial.
Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium
Lancet; 2019 Jul; 394(10195):303-313. PubMed ID: 31204114
[TBL] [Abstract][Full Text] [Related]
9. Impact of etonogestrel implant use on T-cell and cytokine profiles in the female genital tract and blood.
Haddad LB; Swaims-Kohlmeier A; Mehta CC; Haaland RE; Brown NL; Sheth AN; Chien H; Titanji K; Achilles SL; Lupo D; Hart CE; Ofotokun I
PLoS One; 2020; 15(3):e0230473. PubMed ID: 32214321
[TBL] [Abstract][Full Text] [Related]
10. Cervical and systemic concentrations of long acting hormonal contraceptive (LARC) progestins depend on delivery method: Implications for the study of HIV transmission.
Buckner LR; Drobnis EZ; Augustine MS; Rogers LK; Akers J; Mott PD; Hope TJ; Quayle AJ; Schust DJ
PLoS One; 2019; 14(5):e0214152. PubMed ID: 31095572
[TBL] [Abstract][Full Text] [Related]
11. Choice of the levonorgestrel intrauterine device, etonogestrel implant or depot medroxyprogesterone acetate for contraception after aspiration abortion.
Steinauer JE; Upadhyay UD; Sokoloff A; Harper CC; Diedrich JT; Drey EA
Contraception; 2015 Dec; 92(6):553-9. PubMed ID: 26093190
[TBL] [Abstract][Full Text] [Related]
12. Progestin-based contraception regimens modulate expression of putative HIV risk factors in the vaginal epithelium of pig-tailed Macaques.
Bosinger SE; Tharp GK; Patel NB; Zhao C; Payne TL; Dietz Ostergaard S; Butler K; Ellis S; Johnson RL; Kersh EN; McNicholl JM; Vishwanathan SA
Am J Reprod Immunol; 2018 Oct; 80(4):e13029. PubMed ID: 30076667
[TBL] [Abstract][Full Text] [Related]
13. Sex hormones selectively impact the endocervical mucosal microenvironment: implications for HIV transmission.
Goode D; Aravantinou M; Jarl S; Truong R; Derby N; Guerra-Perez N; Kenney J; Blanchard J; Gettie A; Robbiani M; Martinelli E
PLoS One; 2014; 9(5):e97767. PubMed ID: 24830732
[TBL] [Abstract][Full Text] [Related]
14. Behavioral effects of different contraceptive methods and HIV acquisition: an ancillary study of the ECHO randomized trial.
Singata-Madliki M; Lawrie TA; Balakrishna Y; d'Hellencourt FC; Hofmeyr GJ
Reprod Health; 2021 Sep; 18(1):192. PubMed ID: 34587971
[TBL] [Abstract][Full Text] [Related]
15. Influence of Hormonal Contraceptive Use and HIV on Cervicovaginal Cytokines and Microbiota in Malawi.
Haddad LB; Tang JH; Davis NL; Kourtis AP; Chinula L; Msika A; Tegha G; Hosseinipour MC; Nelson JAE; Hobbs MM; Gajer P; Ravel J; De Paris K
mSphere; 2023 Feb; 8(1):e0058522. PubMed ID: 36622252
[TBL] [Abstract][Full Text] [Related]
16. Changes in genital tract immune cell populations after initiation of intrauterine contraception.
Achilles SL; Creinin MD; Stoner KA; Chen BA; Meyn L; Hillier SL
Am J Obstet Gynecol; 2014 Nov; 211(5):489.e1-9. PubMed ID: 24834865
[TBL] [Abstract][Full Text] [Related]
17. Hormonal contraception and HIV-1 infection: medroxyprogesterone acetate suppresses innate and adaptive immune mechanisms.
Huijbregts RP; Helton ES; Michel KG; Sabbaj S; Richter HE; Goepfert PA; Hel Z
Endocrinology; 2013 Mar; 154(3):1282-95. PubMed ID: 23354099
[TBL] [Abstract][Full Text] [Related]
18. Incidence of Herpes Simplex Virus Type 2 Infection Among African Women Using Depot Medroxyprogesterone Acetate, a Copper Intrauterine Device, or a Levonorgestrel Implant for Contraception: A Nested Randomized Trial.
Mugo NR; Stalter RM; Heffron R; Rees H; Scoville CW; Morrison C; Kourtis AP; Bukusi E; Beksinka M; Philip NM; Beesham I; Deese J; Edward V; Donnell D; Baeten JM;
Clin Infect Dis; 2022 Sep; 75(4):586-595. PubMed ID: 34910143
[TBL] [Abstract][Full Text] [Related]
19. Exploring the immunomodulatory role of depot medroxyprogesterones acetate and endogenous progesterone levels in HIV infected and uninfected women.
Mnqonywa N; Abbai N; Ragupathy V; Ramjee G; Hewlett I; Moodley D
BMC Res Notes; 2019 Nov; 12(1):745. PubMed ID: 31730016
[TBL] [Abstract][Full Text] [Related]
20. [Weight variation in users of the levonorgestrel-releasing intrauterine system, of the copper IUD and of medroxyprogesterone acetate in Brazil].
Yela DA; Monteiro IM; Bahamondes LG; Del Castillo S; Bahamondes MV; Fernandes A
Rev Assoc Med Bras (1992); 2006; 52(1):32-6. PubMed ID: 16622536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
